FDA hits first milestone in plan to phase out animal testing
The U.S. Food and Drug Administration (FDA) has reported the successful achievement of its first-year objectives aimed at reducing animal testing in drug development, representing a notable milestone for the in silico medicine community.
The update, released on 20 April 2026, confirms that the agency has delivered on key commitments made in its 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, describing the past year as one of “transformative action” toward more human-relevant science.
The FDA’s initiative reflects a broader effort to modernize preclinical testing by moving away from traditional animal models and toward New Approach Methodologies (NAMs)—a category that includes:
- advanced in vitro systems,
- computational modeling,
- human-derived platforms
These methods are increasingly seen as more predictive of human outcomes, addressing a long-standing issue in drug development: over 90% of drugs that pass animal studies ultimately fail in humans.
For the in silico medicine community, the announcement is highly significant. Computational models—ranging from pharmacokinetic simulations to AI-based toxicity prediction—are explicitly included within NAMs and are increasingly being considered in regulatory submissions.
Notably, recent FDA guidance indicates a willingness to evaluate data from novel computational approaches even before full formal validation, allowing these models to begin building regulatory credibility.
